Lengnau
Biologic manufacturing with highly flexible bioproduction technologies for development through to large scale production
Thermo Fisher’s Lengnau facility is a state-of-the-art multipurpose biomanufacturing site in the heart of Europe. This 1.5m sq. ft. facility leverages highly flexible bioproduction technologies, including stainless steel up to 12,500 L bioreactor capability, providing a pathway from development to large-scale production as your manufacturing needs evolve. The Lengnau team of scientists and technicians provide strategic guidance and flexible solution that are custom built on comprehensive capabilities and expertise.
Lengnau is part of our European network of biologics sites, which includes Groningen, The Netherlands and part of our Global network including Brisbane, Australia, St Louis, Missouri, USA.
Specialized capabilities
- State-of-the-art large molecule
- Strategic guidance and flexible solutions
- Pre-clinical: Custom upstream and downstream process development services
- Clinical supply phases II & III: Technology transfer and process optimization
- Commercial production: 12,500 L scale & coming soon 5,000 L scale
- Capacity to produce up to 120 batches per year
- BPS laboratories for process development, analytical development, 50 L and 250 L pilot batches and manufacturing support for tech transfer and optimization
Site offering
This 1.5 million sq. ft. facility leverages highly flexible bioproduction technologies, including single-use & stainless steel with up to 12’500 L bioreactor capability, providing a pathway from development to large-scale production as your manufacturing needs evolve.
Helpful Resources
Infographic
Inforgraphic
CDMO Checklist to Launch Your Molecule Globally
Preparing to take your drug into the global market? You’ll need to make sure your CDMO has what it takes to successfully navigate the global regulatory space with speed, security, and supply safeguards. Use this quick list as a reference when evaluating your options.
View Infographic
Webinar
Webinar
Navigating the EU regulatory landscape: Accelerating drug development, treatment innovation and market access
During this three-part webinar series, we cover key areas sponsors must be mindful of during drug development in preparation for filing successful regulators submissions.
Watch Webinar
Infographic
Infographic
Getting your biologic to IMPD faster in EMEA
This infographic provides insight into how to balance speed, risk and future needs so as to accelerate your biologic discovery to market in Europe.
Infographic
Infographic
A practical guide to writing robust chemistry, manufacturing, and controls dossier modules to support first-in-human trials
Do you need to get your first-in-human (FIH) paperwork in order? This informative checklist can help you draft phase-appropriate chemistry, manufacturing, and controls (CMC) modules for the common technical document (CTD).